Prolonged response to treatment with trabectedin in a patent with a diagnosis of advanced synovial sarcoma

Abstract

Trabectedin is a new drug with a complex mechanism of action that has demonstrated efficacy in the treatment of
patients diagnosed with advanced soft tissue sarcoma, after failure of chemotherapy based on anthracyclines and
ifosfamide. In Poland, in contrast to many other EU countries, reimbursement of this drug includes only subtypes
of liposarcoma and leiomyosarcoma. We describe a case of a young man with a diagnosis of different subtype
of soft tissue sarcoma: metastatic synovial sarcoma, in which the use of trabectedin resulted in long-term clinical
benefit after previous treatment with multiple lines of chemotherapy based on the standard chemotherapeutics
used in this sarcoma subtype.